The RETApro Research Team is RETApro’s in-house editorial and laboratory group. We write and review the pages in our research library — the material on retatrutide’s mechanism, its place in the incretin class, and how to evaluate a research-compound supplier — and we are responsible for their scientific accuracy and for keeping their regulatory framing honest.
We are not clinicians, and nothing we publish is medical advice. Our remit is the pharmacology, chemistry, and quality assurance of a compound supplied strictly for laboratory research use.
How we review
Primary sources, cited and dated
Every clinical or pharmacological claim is traced to peer-reviewed primary literature or a named regulator, with an attributed and dated reference. We verify each DOI against the source before publishing rather than repeating figures second-hand.
Regulatory status stated plainly
We describe retatrutide as what it is — an investigational compound that is not approved by any regulator, supplied for laboratory research use only. We do not imply availability for human use or present trial figures as product benefits.
Pharmacology, not protocols
Our library covers receptor pharmacology, structure, handling, and supplier due-diligence. It contains no human dosing, administration, or titration guidance — that is outside the scope of research-use material.
Uncertainty acknowledged
Where the science is unsettled, we say so. Naming open questions is more honest, and more useful to a researcher, than overstating what is known.
The research library
Our reviewed articles are collected in the RETApro research hub. Each carries this team’s byline and a “last reviewed” date: